comparemela.com

Latest Breaking News On - Promising preliminary safety - Page 1 : comparemela.com

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients. | June 9, 2023

United kingdomUnited statesRabi hannaBaisong meiEuropean hematology associationEditas medicine incBroad instituteBroad institute casDepartment of pediatric hematology oncologyHarvard university casCongress onHybrid congressSenior vice presidentChief medical officerPediatric hematology oncologyMarrow transplantation

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Company-sponsored webinar to be announcedCAMBRIDGE, Mass., May 11, 2023 Editas Medicine, Inc. , a clinical stage genome editing company, today announced that a scientific abstract detailing. | May 11, 2023

United statesUnited kingdomBaisong meiRabi hannaHarvard university casDepartment of pediatric hematology oncologyEuropean hematology association congressBroad institute casEuropean hematology associationEditas medicine incBroad instituteHybrid congressSenior vice presidentChief medical officerPresentation detailsPromising preliminary safety

vimarsana © 2020. All Rights Reserved.